Skip to main content
OpenTrials
Completed

NCT Number: NCT04568707

Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES)

Patients with neurological or psychiatric symptoms or pre-existing disease will be sampled (blood for serum and DNA or saliva for DNA) at inclusion and at M6 (blood) and M12 (blood) depending on their pathology. Sampling will be done either at hospital if patient is on site for routine care or at home if no consultation is scheduled at hospital.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 Autoimmune Diseases Autoimmune Diseases of the Nervous System Basal Ganglia Diseases Brain Diseases COVID-19 Central Nervous System Diseases Coronaviridae Infections Coronavirus Infections Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Infections Lung Diseases Mental Disorders Movement Disorders Multiple Sclerosis Nervous System Diseases Neurodegenerative Diseases Neurologic Manifestations Nidovirales Infections Parkinson Disease Parkinsonian Disorders Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral Psychiatric Manifestations RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Synucleinopathies Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Pitié Salpétrière

Paris, 75013, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Age over 18 yo
  • Patient having presented or presenting a Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period
  • And patient with:
  • a neurological or psychiatric manifestation de novo during or after the Covid-19 infection and/or
  • either a chronic neurological or psychiatric pathology

Treatment and study plan

blood sample

Other

blood sample for serum (serology, biomarkers) and DNA

Primary outcomes

  1. dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients

    Time frame: 12 months

    dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients

Secondary outcomes

  1. Serum neurofilaments

    Time frame: 12 months

    Neurodegenerative markers (e.g., neurofilaments) associated with a neurological or psychiatric manifestation of Covid-19 infection

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Paris Brain Institute (ICM)

Registry information

Official study title

Evaluation of Biological Response to SARS-COV2 in Patients With Pre-existing Neurological Disease or With New Neurological Manifestations of COVID-19

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Sep 29, 2020
Registry last updated
Feb 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.